Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 857-862

  Jin, Minfei ^a   Yang, Zujing ^a   Ye, Weiping ^a   Yu, Xiaowei ^b   Hua, Xiaolin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cervix; EZH2; Histone methyltransferase; Immunohistochemistry; Prognosis

Indexed keywords

HISTONE METHYLTRANSFERASE; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

EID: 84931396492     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3319     Document Type: Article

References (28)

1. Vizcaino AP, Moreno V, Bosch FX, et al: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86: 429-435, 2000.
2. Koutsky L: Epidemiology of genital human papillomavirus infection. Am J Med 102: 3-8, 1997.
3. Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22: 3113-3119, 2004.
4. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
5. Simon JA: Transcription. Sweet silencing. Science 325: 45-46, 2009.
6. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell 118: 409-418, 2004.
7. Wei Y, Chen YH, Li LY, et al: CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 13: 87-94, 2011.
8. Chen S, Bohrer LR, Rai AN, et al: Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 12: 1108-1114, 2010.
9. Viré E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006.
10. Gieni RS and Hendzel MJ: Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem Cell Biol 87: 711-746, 2009.
11. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
12. Gong Y, Huo L, Liu P, et al: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117: 5476-5484, 2011.
13. Cao W, Feng Z, Cui Z, et al: Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 118: 2858-2871, 2012.
14. Cao W, Younis RH, Li J, et al: EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res (Phila) 4: 1816-1824, 2011.
15. Cao W, Ribeiro Rde O, Liu D, et al: EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One 7: e52984, 2012.
16. Kikuchi J, Kinoshita I, Shimizu Y, et al: Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116: 3015-3024, 2010.
17. Huqun, Ishikawa R, Zhang J, et al: Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 118: 1599-1606, 2012.
18. He LR, Liu MZ, Li BK, et al: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 127: 138-147, 2010.
19. Hinz S, Weikert S, Magheli A, et al: Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol 182: 2920-2925, 2009.
20. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 18: 298-301, 2012.
21. Hou T, Liang D, Xu L, et al: Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer. Gynecol Oncol 130: 181-187, 2013.
22. Shibata D: Mutation and epigenetic molecular clocks in cancer. Carcinogenesis 32: 123-128, 2011.
23. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell 118: 409-418, 2004.
24. Zhou J, Roh JW, Bandyopadhyay S, et al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 128: 344-348, 2013.
25. Li H, Bitler BG, Vathipadiekal V, et al: ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) 5: 484-491, 2012.
26. Chen SQ, Zhang HM, Li JB, et al: Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma. Int J Gynecol Cancer 24: 1653-1658, 2014.
27. Fang J, Zhang M and Li Q: Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Am J Med Sci 342: 198-204, 2011.
28. Breuer RH, Snijders PJ, Smit EF, et al: Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736-743, 2004.